Breaking News Instant updates and real-time market news.

IMXI

International Money Express

$14.37 /

-1.45 (-9.17%)

18:57
09/30/20
09/30
18:57
09/30/20
18:57

International Money Express 4.925M share Secondary priced at $13.50

The deal priced below the last closing price of $14.36. Credit Suisse is acting as lead book running manager for the offering.

  • 01

    Oct

IMXI International Money Express
$14.37 /

-1.45 (-9.17%)

08/17/20 BTIG
International Money Express price target raised to $22 from $17 at BTIG
08/05/20 Cantor Fitzgerald
International Money price target raised to $21 from $11 at Cantor Fitzgerald
08/05/20 JMP Securities
International Money Express upgraded to Outperform at JMP Securities
08/05/20 JMP Securities
International Money upgraded to Outperform from Market Perform at JMP Securities

TODAY'S FREE FLY STORIES

Periodicals
Blackstone to buy Simply Self storage for $1.2B, WSJ reports » 17:47
10/25/20
10/25
17:47
10/25/20
17:47
BX

Blackstone

$54.59 /

-0.17 (-0.31%)

, BAM

Brookfield

$33.89 /

+0.025 (+0.07%)

Blackstone (BX) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

06/25/20
Fly Intel: Top five analyst initiations
06/25/20 UBS
Blackstone initiated with a Buy at UBS
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Blackstone downgraded to Neutral from Buy at Citi
BAM Brookfield
$33.89 /

+0.025 (+0.07%)

10/23/20 Credit Suisse
Athene could still bid for American Equity, faces 'hurdles,' says Credit Suisse
10/19/20
Fly Intel: Top five analyst upgrades
10/19/20 Citi
Brookfield upgraded to Buy from Neutral at Citi
09/23/20 JPMorgan
Brookfield shares remain undervalued, says JPMorgan
BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

BAM Brookfield
$33.89 /

+0.025 (+0.07%)

BX Blackstone
$54.59 /

-0.17 (-0.31%)

Periodicals
Facebook preparing measures for possible election unrest, WSJ says » 17:43
10/25/20
10/25
17:43
10/25/20
17:43
FB

Facebook

$284.89 /

+6.78 (+2.44%)

Facebook teams have…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

10/22/20 Argus
Snap price target raised to $50 from $30 at Argus
10/20/20 Jefferies
Facebook price target raised to $320 from $310 at Jefferies
10/20/20 Credit Suisse
Facebook price target raised to $322 from $315 at Credit Suisse
10/15/20 Cowen
Trump unhappiness may reinforce odds of antitrust action on Facebook, says Cowen
FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

FB Facebook
$284.89 /

+6.78 (+2.44%)

Periodicals
Apple Services business could be hit in Google antitrust battle, WSJ reports » 17:38
10/25/20
10/25
17:38
10/25/20
17:38
GOOG

Alphabet

$1,640.50 /

+25.89 (+1.60%)

, GOOGL

Alphabet Class A

$1,632.77 /

+24.75 (+1.54%)

, AAPL

Apple

$115.05 /

-0.77 (-0.66%)

The Justice…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

10/23/20 Cleveland Research
Alphabet upgraded to Buy on Search, Cloud momentum at Cleveland Research
10/22/20 Jefferies
Jefferies says 71% of Google users would still use search if removed from device
10/21/20 JPMorgan
Alphabet arguments against lawsuit have merits, says JPMorgan
10/21/20 Morgan Stanley
Slack downgraded to Underweight on rising competitive risk at Morgan Stanley
GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

10/23/20 Cleveland Research
Alphabet upgraded to Buy on Search, Cloud momentum at Cleveland Research
10/23/20 Cleveland Research
Alphabet Class A upgraded to Buy from Neutral at Cleveland Research
10/22/20 Jefferies
Jefferies says 71% of Google users would still use search if removed from device
10/21/20 JPMorgan
Alphabet arguments against lawsuit have merits, says JPMorgan
AAPL Apple
$115.05 /

-0.77 (-0.66%)

10/22/20 Cleveland Research
Cleveland Research sees further upside for Apple iPhone forecasts
10/22/20 DA Davidson
Apple 'looks good to us', says DA Davidson
10/22/20 Morgan Stanley
Apple iPhone12 cycle early data points trending positively, says Morgan Stanley
10/22/20 Piper Sandler
Apple price target raised to $135 from $130 at Piper Sandler
GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOG Alphabet
$1,640.50 /

+25.89 (+1.60%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

GOOGL Alphabet Class A
$1,632.77 /

+24.75 (+1.54%)

AAPL Apple
$115.05 /

-0.77 (-0.66%)

Hot Stocks
Coca-Cola European Partners announces proposed acquisition of Coca-Cola Amatil » 17:19
10/25/20
10/25
17:19
10/25/20
17:19
CCEP

Coca-Cola European Partners

$39.00 /

-0.485 (-1.23%)

, CCLAY

Coca-Cola Amatil

$0.00 /

+ (+0.00%)

, KO

Coca-Cola

$50.52 /

-0.15 (-0.30%)

Coca-Cola European…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

07/06/20 ABN Amro
Coca-Cola European Partners upgraded to Buy from Hold at ABN Amro
06/22/20 Citi
Citi calls Coca-Cola European Partners its Top Pick in Beverages
06/10/20 ABN Amro
Coca-Cola European Partners upgraded to Hold from Sell at ABN Amro
06/05/20 HSBC
Coca-Cola European Partners initiated with a Hold at HSBC
CCLAY Coca-Cola Amatil
$0.00 /

+ (+0.00%)

10/21/20 JPMorgan
Coca-Cola Amatil upgraded to Overweight from Neutral at JPMorgan
08/06/20 Goldman Sachs
Coca-Cola Amatil upgraded to Buy from Neutral at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Coca-Cola Amatil upgraded to Neutral from Sell at Goldman Sachs
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

10/23/20 Morgan Stanley
Coca-Cola price target raised to $57 from $54 at Morgan Stanley
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/12/20 Citi
PepsiCo upgraded to Buy from Neutral at Citi
09/28/20 Morgan Stanley
PepsiCo trading at good entry point ahead of earnings, says Morgan Stanley
KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

CCEP Coca-Cola European Partners
$39.00 /

-0.485 (-1.23%)

CCLAY Coca-Cola Amatil
$0.00 /

+ (+0.00%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

KO Coca-Cola
$50.52 /

-0.15 (-0.30%)

Periodicals
Amazon wins order to stall $3.4B Reliance-Future deal, Bloomberg says » 17:12
10/25/20
10/25
17:12
10/25/20
17:12
AMZN

Amazon.com

$3,203.69 /

+28.72 (+0.90%)

Amazon.com secured relief…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

10/20/20 Citi
Citi likes Amazon head of Q3 results despite Prime Day language
10/19/20 Piper Sandler
Amazon Prime Day sales up 49% year-over-year, says Piper Sandler
10/16/20 Citi
Citi questions if Amazon's Prime Day may disappoint compared to last year
10/15/20 Truist
Truist says indications show Amazon Prime Day again a 'record sales period'
AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

AMZN Amazon.com
$3,203.69 /

+28.72 (+0.90%)

Periodicals
Carlyle nearing $2.4B deal for Siemen's Flender business, Bloomberg says » 17:09
10/25/20
10/25
17:09
10/25/20
17:09
CG

Carlyle Group

$27.50 /

-0.2 (-0.72%)

, SIEGY

Siemens

$0.00 /

+ (+0.00%)

Carlyle Group (CG) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

10/13/20 Citi
Carlyle Group upgraded to Buy from Neutral at Citi
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
06/08/20 Citi
Carlyle Group downgraded to Neutral from Buy at Citi
04/15/20
Fly Intel: Top five analyst upgrades
SIEGY Siemens
$0.00 /

+ (+0.00%)

10/09/20 JPMorgan
Siemens Q4 numbers not likely an important catalyst, says JPMorgan
10/06/20 Vertical Research
Siemens upgraded to Buy from Hold at Vertical Research
10/02/20 UBS
Siemens price target lowered to EUR 122 from EUR 134 at UBS
09/29/20 Deutsche Bank
Siemens price target lowered to EUR 123 from EUR 135 at Deutsche Bank
CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

CG Carlyle Group
$27.50 /

-0.2 (-0.72%)

SIEGY Siemens
$0.00 /

+ (+0.00%)

Periodicals
Dunkin' Brands near deal for $9B sale to Inspire Brands, NYTimes reports » 17:06
10/25/20
10/25
17:06
10/25/20
17:06
DNKN

Dunkin' Brands

$88.70 /

-0.5 (-0.56%)

Dunkin' Brands, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

10/23/20 KeyBanc
Dunkin' Brands price target raised to $97 from $78 at KeyBanc
10/20/20 Cleveland Research
Dunkin' Brands U.S. comps look to have improved, says Cleveland Research
10/19/20 Wells Fargo
Dunkin' Brands price target raised to $83 from $67 at Wells Fargo
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

Hot Stocks
Dunkin' Brands confirms preliminary discussions to be acquired by Inspire Brands » 16:51
10/25/20
10/25
16:51
10/25/20
16:51
DNKN

Dunkin' Brands

$88.70 /

-0.5 (-0.56%)

Dunkin' Brands, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

10/23/20 KeyBanc
Dunkin' Brands price target raised to $97 from $78 at KeyBanc
10/20/20 Cleveland Research
Dunkin' Brands U.S. comps look to have improved, says Cleveland Research
10/19/20 Wells Fargo
Dunkin' Brands price target raised to $83 from $67 at Wells Fargo
10/06/20 Piper Sandler
Piper teen survey shows Snap, Amazon and Apple remain favorites
DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

DNKN Dunkin' Brands
$88.70 /

-0.5 (-0.56%)

Recommendations
China Tesla car recall seems 'a pretty big deal,' says GLJ Research » 16:29
10/25/20
10/25
16:29
10/25/20
16:29
TSLA

Tesla

$420.61 /

-5.22 (-1.23%)

Commenting on the…

Commenting on the reported 50K China Tesla car recall, GLJ Research analyst Gordon Johnson says he thinks "the entire China initiative for TSLA is falling apart." The analyst argues that Elon Musk made promises "it seems he will not be able to keep to the Chinese government." "What's important about the recall isn't its impressive size, it's that it is happening at all," Johnson adds, noting that it is "a 100% elective action by China." The analyst believes this "is a big deal," and likely why despite $6B more in cash in Q3 versus Q2, Tesla's interest income was down 25% quarter-over-quarter.

ShowHide Related Items >><<
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

10/23/20 Morgan Stanley
Tesla price target raised to $360 from $333 at Morgan Stanley
10/22/20
Fly Intel: Top five analyst upgrades
10/22/20 GLJ Research
GLJ keeps $40 target on Tesla, says business model not sustainable
10/22/20 RBC Capital
Tesla price target raised to $339 from $290 at RBC Capital
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

  • 14
    Feb
TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

TSLA Tesla
$420.61 /

-5.22 (-1.23%)

Earnings
SAP lowers FY20 revenue guidance to EUR 27.2-EUR 27.8B, from EUR 27.8B-EUR 28.5B » 16:21
10/25/20
10/25
16:21
10/25/20
16:21
SAP

SAP

$149.68 /

+2.15 (+1.46%)

SAP said in a statement…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

10/08/20 JPMorgan
SAP expected to give Qualtrics update with Q3 results, says JPMorgan
07/28/20 JPMorgan
SAP price target raised to EUR 160 from EUR 125 at JPMorgan
07/28/20 Credit Suisse
SAP price target raised to EUR 157 from EUR 135 at Credit Suisse
07/28/20 BMO Capital
SAP price target raised to $170 from $130 at BMO Capital
SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

SAP SAP
$149.68 /

+2.15 (+1.46%)

Earnings
Celanese expects FY20 adjusted EPS of $7-$7.10, consensus $6.99 » 16:16
10/25/20
10/25
16:16
10/25/20
16:16
CE

Celanese

$120.09 /

+2.065 (+1.75%)

"Across most of our…

"Across most of our end markets, global demand during the third quarter progressed well along the path of recovery," said Lori Ryerkerk, Celanese's chairman and chief executive officer. "We are monitoring the current resurgence of COVID-19 across various locations for any impact to our businesses. At this stage, the October and November order books are shaping consistently with the third quarter and show no indications of demand retraction. We expect continued momentum in the fourth quarter to partially offset various sequential headwinds including normal December seasonality and a major turnaround at our Frankfurt POM facility. Including all these factors, we expect full year 2020 adjusted earnings of approximately $7.00 to $7.10 per share. Looking to 2021, we remain confident that underlying demand will reach pre-COVID levels at some point in the year. While uncertainty remains, we continue to be focused on controllable actions to drive strong growth next year, including productivity, production planning, and disciplined capital deployment."

ShowHide Related Items >><<
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
09/21/20 Evercore ISI
Celanese initiated with an Outperform at Evercore ISI
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

Earnings
Celanese reports Q3 adjusted EPS $1.95, consensus $1.70 » 16:14
10/25/20
10/25
16:14
10/25/20
16:14
CE

Celanese

$120.09 /

+2.065 (+1.75%)

Reports Q3 revenue $1.4B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
10/07/20 KeyBanc
Celanese upgraded to Overweight from Sector Weight at KeyBanc
09/21/20 Evercore ISI
Celanese initiated with an Outperform at Evercore ISI
CE Celanese
$120.09 /

+2.065 (+1.75%)

CE Celanese
$120.09 /

+2.065 (+1.75%)

Hot Stocks
Mirati reports preliminary results from mutant KRAS selective inhibitor programs » 16:10
10/25/20
10/25
16:10
10/25/20
16:10
MRTX

Mirati Therapeutics

$180.37 /

+0.13 (+0.07%)

Mirati Therapeutics…

Mirati Therapeutics announced preliminary results from the company's mutant KRAS selective inhibitor programs. The preliminary results included updated clinical data of adagrasib, the company's KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics and initial preclinical in vivo data of MRTX1133, the company's selective and potent potential first-in-class KRAS G12D inhibitor. In a pooled assessment of 110 patients harboring a G12C mutation in NSCLC, CRC and other solid tumors, monotherapy adagrasib has been well tolerated. 4.5% of treatment-related adverse events led to discontinuation. Over 50 patients have been treated with adagrasib in combination with either pembrolizumab in NSCLC, cetuximab in CRC and TNO-155 in NSCLC or CRC. Each combination has been well tolerated. The pembrolizumab and cetuximab combination cohorts are ongoing and each have cleared the dose limiting toxicity evaluation period at the full dose of each commercial agent and at a 600 mg BID dose of adagrasib. The TNO-155 combination dose escalation and expansion cohorts are ongoing at a 600 mg BID dose of adagrasib. Regarding preliminary efficacy data as of August 30, 2020 in patients with advanced NSCLC treated with adagrasib as a monotherapy at a 600 mg BID dose: Patients had a median of two prior systemic treatments, including all patients receiving prior treatment with platinum-based chemotherapy regimens and 92% of patients receiving prior treatment with an anti-PD-1 /L1 inhibitor. 4 of 6 responders have a duration of treatment for greater than 11 months and all 4 patients remain on treatment. Preliminary explorative correlative analysis of co-mutations of KRAS G12C and STK11 in advanced NSCLC showed a 64% ORR across pooled Phase 1/1b and Phase 2 cohorts. Approximately 30% of all KRAS G12C mutant NSCLC patients have a STK11 co-occurring mutation. Co-occurring KRAS and STK11 mutations have been shown to be significantly correlated with poor clinical outcomes when treated with immunotherapy and platinum-based chemotherapy regimens. In a case study presented from the ongoing clinical trial of adagrasib as a monotherapy, a heavily pre-treated NSCLC patient with an unirradiated, active brain metastases observed a 67% reduction in tumor volume including the disappearance of a metastatic brain lesion. Preclinical studies demonstrate dose-dependent brain and cerebrospinal fluid exposure. The Phase 2 cohort of adagrasib as a monotherapy is currently enrolling additional NSCLC patients with active brain metastases to further explore this patient population which has a high unmet medical need. In a case study presented from the ongoing clinical trial of adagrasib in combination with TNO-155 in collaboration with Novartis, a heavily pre-treated NSCLC patient treated in the combination trial of adagrasib and TNO-155 observed a 60% reduction in tumor volume.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

10/21/20 BMO Capital
Mirati Therapeutics price target raised to $176 from $101 at BMO Capital
10/08/20 Credit Suisse
Mirati Therapeutics price target raised to $190 from $140 at Credit Suisse
09/28/20 BofA
Mirati Therapeutics initiated with a Neutral at BofA
09/28/20 BofA
Mirati Therapeutics initiated with a Neutral at BofA
MRTX Mirati Therapeutics
$180.37 /

+0.13 (+0.07%)

  • 10
    Jan
Hot Stocks
Cenovus Energy, Husky Energy combine to create oil, natural gas company » 16:02
10/25/20
10/25
16:02
10/25/20
16:02
CVE

Cenovus Energy

$3.72 /

-0.03 (-0.80%)

Cenovus Energy and Husky…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

10/20/20 Morgan Stanley
Cenovus Energy price target lowered to C$6 from C$8 at Morgan Stanley
10/16/20 National Bank
Cenovus Energy price target lowered to C$8 from C$11 at National Bank
10/01/20
Fly Intel: Top five analyst downgrades
10/01/20 JPMorgan
Cenovus downgraded to Underweight on valuation, leverage at JPMorgan
CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

CVE Cenovus Energy
$3.72 /

-0.03 (-0.80%)

Hot Stocks
Essa Pharma presents therapeutics potential of EPI-7386 » 15:55
10/25/20
10/25
15:55
10/25/20
15:55
EPIX

Essa Pharma

$6.20 /

-0.26 (-4.02%)

Essa Pharma presented new…

Essa Pharma presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics. In an in vitro cellular thermal shift assay, EPI-7386 was shown to physically interact with the both the full-length and the splice variant form of the androgen receptor. In an in vitro full-length AR-driven cellular model, RNAseq data was analyzed by pathway enrichment analysis. EPI-7386 demonstrates largely similar modulation of AR-regulated genes compared to enzalutamide, but with additional unique elements. EPI-7386 exhibits superior activity to enzalutamide in the AR-V7-driven cellular models LNCaP95 and 22Rv1 by modulating AR-driven gene expression with or without the addition of an external androgen.

ShowHide Related Items >><<
EPIX Essa Pharma
$6.20 /

-0.26 (-4.02%)

  • 29
    Jul
Hot Stocks
Lianluo Smart Limited, Newegg announce entering into merger agreement » 15:52
10/25/20
10/25
15:52
10/25/20
15:52
LLIT

Lianluo Smart Limited

$0.41 /

-0.0593 (-12.75%)

Lianluo Smart Limited and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLIT Lianluo Smart Limited
$0.41 /

-0.0593 (-12.75%)

Hot Stocks
Turning Point Therapeutics presents initial data from Phase 1 SHIELD-1 study » 15:46
10/25/20
10/25
15:46
10/25/20
15:46
TPTX

Turning Point Therapeutics

$102.72 /

+0.82 (+0.80%)

Turning Point…

Turning Point Therapeutics reported initial clinical data from the ongoing Phase 1 dose finding portion of its SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R. The initial data highlighted preliminary clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile. Twenty-two patients were treated across four dose levels from Sept. 2019 to the data cut-off date of Oct. 15, 2020. Patients included those with MET-altered non-small cell lung cancer, colorectal cancer, gastric or gastroesophageal junction cancer and glioblastoma. The median number of prior therapies was three, with all patients having received at least one prior line of chemotherapy and/or immunotherapy and the majority of patients having received multiple rounds of prior combination chemotherapy. Sixty-eight percent of patients had a baseline ECOG performance score of 1. Preliminary efficacy data was available for 15 evaluable patients with baseline measurable disease and at least one post-baseline scan. TPX-0022 was generally well tolerated, with the most frequent treatment emergent adverse event being Grade 1 or 2 dizziness. Of 10 MET TKI-naive patients, five achieved a partial response, including three with GC or GEJ cancer, one with CRC, and one with NSCLC. All three evaluable patients with gastric or GEJ tumors achieved a response. Of the five responses, three patients achieved a confirmed response, and two patients remained on treatment in a response awaiting confirmation at the time of the data cut-off. Of the five MET TKI-pretreated NSCLC patients, three patients treated with multiple rounds of prior therapy achieved a best response of stable disease with two patients showing tumor measurement improvements. Nine of 15 patients achieved clinical benefit. Six of 15 patients remained on treatment with duration of treatment ranging from 7.6+ to 34+ weeks. The company anticipates initiating Phase 1 dose expansion after determining the recommended Phase 2 dose. Turning Point plans to discuss the ongoing Phase 1 SHIELD-1 study with the Food and Drug Administration to potentially modify the trial into a registrational Phase 1/2 design. The company is targeting initiation of the Phase 2 portion in the second half of 2021, pending FDA feedback. In parallel, based on the SHIELD-1 study initial findings, a combination study with TPX-0022 and an epidermal growth factor receptor tyrosine kinase inhibitor in patients with EGFR mutated MET-amplified NSCLC is also planned for initiation in the second half of 2021. In addition, preclinical data for the company's lead drug candidate repotrectinib were reported in two poster presentations. The first poster expanded on previous work presented in June at AACR 2020 with additional preclinical data of repotrectinib in combination with the KRAS-G12C inhibitor, AMG-510, in a NSCLC xenograft tumor model. In preclinical studies, repotrectinib significantly enhanced efficacy of AMG-510 and showed a marked survival benefit in a KRAS G12C xenograft model when compared to AMG-510 alone. Repotrectinib previously showed synergy in preclinical models with AMG-510 and inhibited KRAS G12C tumor cell proliferation, suppressed receptor tyrosine kinase upregulation induced by AMG-510, and reduced KRAS G12C tumor cell cytokine release. Similar results have since been obtained with other KRAS G12C inhibitors. With the new results presented in a KRAS G12C xenograft tumor model, and previous data shown with repotrectinib in combination with a MEK inhibitor, the company now plans to initiate a clinical combination study in KRAS mutant NSCLC in mid-2021. Further details on the design will be shared at the time of study initiation. The second poster showed preclinical studies of repotrectinib as monotherapy and in combination with irinotecan and temozolomide in neuroblastoma cell lines and pediatric patient-derived xenograft models. Repotrectinib combined with chemotherapy demonstrated increased anti-tumor activity compared to chemotherapy alone in an ALK-mutant neuroblastoma PDX model.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
08/21/20 Canaccord
Turning Point Therapeutics price target raised to $85 from $80 at Canaccord
08/19/20 Roth Capital
Turning Point Therapeutics price target raised to $77 from $75 at Roth Capital
07/13/20 Roth Capital
Roth Capital positive on Turning Point Therapeutics appointment of Partridge
TPTX Turning Point Therapeutics
$102.72 /

+0.82 (+0.80%)

  • 19
    May
Hot Stocks
Revolution Medicines reports progress, expansion of combo strategy with RMC-4630 » 15:39
10/25/20
10/25
15:39
10/25/20
15:39
RVMD

Revolution Medicines

$40.39 /

+1.17 (+2.98%)

, AZN

AstraZeneca

$52.01 /

+0.03 (+0.06%)

Revolution Medicines…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

  • 09
    Jul
  • 13
    Feb
AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

RVMD Revolution Medicines
$40.39 /

+1.17 (+2.98%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

AZN AstraZeneca
$52.01 /

+0.03 (+0.06%)

Hot Stocks
Syros presents initial data from Phase 1 trial of SY-5609 » 15:34
10/25/20
10/25
15:34
10/25/20
15:34
SYRS

Syros Pharmaceuticals

$7.55 /

+0.135 (+1.82%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced initial safety, pharmacokinetics and pharmacodynamics data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose for continuous daily dosing. The data was presented in a poster session at the 32nd EORTC-NCI-AACR Symposium. The study also includes a cohort evaluating SY-5609 in combination with fulvestrant in CDK4/6 inhibitor-resistant HR-positive breast cancer patients. As of August 21, 17 patients had been enrolled in the trial and were eligible for safety, PK and PD analysis. Patients were either treated with continuous daily dosing of single-agent SY-5609 at 1, 3, 4 or 5 mg, or for three weeks on and one week off at 3 mg in combination with fulvestrant. The median age of the patients enrolled in the study was 64. Patients were heavily pretreated with a median of four prior therapies. The MTD for continuous daily dosing was achieved at 3 mg. The data showed that SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity. Notably, increases in POLR2A in patients treated at 3 mg daily reached levels associated with tumor regressions in preclinical models, as well as with levels of CDK7 target engagement at which a clinical response and apoptosis were observed in a trial of patients treated with a first-generation IV CDK7 inhibitor. SY-5609 demonstrated approximately dose-proportional PK as both a single agent and in combination, minimal accumulation with repeat dosing, and a steady state half-life compatible with once-daily dosing. The majority of adverse events reported with SY-5609 as a single agent were low grade. The most common AEs were nausea, diarrhea, fatigue, platelet count decrease, and vomiting. The safety profile of SY-5609 in combination with fulvestrant was consistent with that of single-agent SY-5609. Five of the 13 patients treated with single-agent SY-5609 were response evaluable, and of those, three achieved stable disease and two had progressive disease; one of the four patients treated in the combination cohort was response evaluable and had progressive disease. The Phase 1 trial continues to actively enroll patients with select solid tumors, including the recently expanded single-agent cohort in lung cancer patients and combination cohort in breast cancer patients, to further evaluate the 3 mg daily dose in focused patient populations. The trial has also been opened to patients with advanced pancreatic cancer, another tumor type that has demonstrated sensitivity to SY-5609 in preclinical models. Additional cohorts are evaluating alternate regimens, supported by preclinical data showing that intermittent regimens of SY-5609 induced tumor regressions. Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

Hot Stocks
Aileron announces proof-of-concept data from ALRN-6924 Phase 1b trial » 15:31
10/25/20
10/25
15:31
10/25/20
15:31
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Aileron Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun
Hot Stocks
Momo announces Yan Tang as Executive Chairman, Li Wang as new CEO » 15:13
10/25/20
10/25
15:13
10/25/20
15:13
MOMO

Momo

$15.22 /

+0.56 (+3.82%)

Momo announced that its…

Momo announced that its board of directors has approved Yan Tang to step down from the position of Chief Executive Officer, and promoted Li Wang to this position, effective on November 1, 2020. Wang is a director of the Company, currently serving as the President and Chief Operating Officer of Momo. Starting from November 1, 2020, Yan Tang will become the executive chairman of the board of directors of Momo, in which role he will continue to be integrally involved in setting the strategic priorities and directing new business initiatives for Momo.

ShowHide Related Items >><<
MOMO Momo
$15.22 /

+0.56 (+3.82%)

09/04/20
Fly Intel: Top five analyst initiations
09/04/20
Fly Intel: Top five analyst downgrades
09/04/20 86 Research
Momo initiated with a Buy at 86 Research
09/04/20 Morgan Stanley
Momo downgraded to Equal Weight on core business risk at Morgan Stanley
MOMO Momo
$15.22 /

+0.56 (+3.82%)

MOMO Momo
$15.22 /

+0.56 (+3.82%)

MOMO Momo
$15.22 /

+0.56 (+3.82%)

Conference/Events
RenovaCare to host conference call » 12:31
10/25/20
10/25
12:31
10/25/20
12:31
RCAR

RenovaCare

$0.00 /

+ (+0.00%)

Management holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCAR RenovaCare
$0.00 /

+ (+0.00%)

Conference/Events
Koppers Holdings to host conference call » 12:26
10/25/20
10/25
12:26
10/25/20
12:26
KOP

Koppers Holdings

$25.17 /

+0.67 (+2.73%)

Conference call to…

Conference call to provide a business update for August 2020 will be held on October 26 at 11 am. Webcast Link

ShowHide Related Items >><<
KOP Koppers Holdings
$25.17 /

+0.67 (+2.73%)

KOP Koppers Holdings
$25.17 /

+0.67 (+2.73%)

06/19/20 Barrington
Koppers Holdings price target raised to $30 from $25 at Barrington
06/19/20 Barrington
Koppers Holdings price target raised to $30 from $25 at Barrington
02/28/20 Barrington
Koppers Holdings price target lowered to $43 from $50 at Barrington
11/11/19 Barrington
Koppers Holdings price target raised to $50 from $35 at Barrington
KOP Koppers Holdings
$25.17 /

+0.67 (+2.73%)

Upgrade
PTT Exploration upgraded to Neutral from Sell at Goldman Sachs » 12:18
10/25/20
10/25
12:18
10/25/20
12:18
PEXNY

PTT Exploration

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PEXNY PTT Exploration
$0.00 /

+ (+0.00%)

03/17/20 Nomura
PTT Exploration downgraded to Neutral from Buy at Nomura Instinet
Conference/Events
Aileron Therapeutics to host conference call » 11:33
10/25/20
10/25
11:33
10/25/20
11:33
ALRN

Aileron Therapeutics

$1.92 /

-0.19 (-9.00%)

Management will discuss…

Management will discuss the Company's presentation at the 32nd EORTC-NCI-AACR Virtual Symposium on a conference call to be held on October 26 at 8:30 am. Webcast Link

ShowHide Related Items >><<
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

06/05/20 H.C. Wainwright
Aileron Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
04/08/20 JonesTrading
Aileron Therapeutics initiated with a Buy at JonesTrading
ALRN Aileron Therapeutics
$1.92 /

-0.19 (-9.00%)

  • 04
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.